Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

86.25 -0.25 (-0.29%)

Streaming Delayed Price Updated: 9:30 AM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction ↗

September 02, 2025

Ionis posted positive Phase 3 results for olezarsen in severe hypertriglyceridemia, showing 72% triglyceride reduction and 85% fewer pancreatitis events.

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

September 02, 2025

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Ionis Pharma Hits The 'Bull Case,' 'Blue Sky' In Lowering Triglycerides. Shares Launch. ↗

September 02, 2025

Ionis Pharmaceuticals scored the "bull case" Tuesday after its experimental treatment for high triglycerides beat the placebo.

Via Investor's Business Daily

Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)

September 02, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy ↗

August 21, 2025

Via Stocktwits

Earnings Scheduled For July 30, 2025 ↗

July 30, 2025

Via Benzinga

IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Presents a High-Probability Technical Breakout Setup ↗

August 30, 2025

IONIS Pharmaceuticals (IONS) shows strong technicals with a high setup rating, signaling a potential breakout from its current consolidation pattern.

Via Chartmill

What's Going On With Takeda Stock On Friday? ↗

August 22, 2025

Takeda stock steadies after early dip as FDA clears Ionis' Dawnzera for hereditary angioedema, posing fresh competition to Takeda's Takhzyro.

Via Benzinga

Beyond The Numbers: 10 Analysts Discuss Ionis Pharmaceuticals Stock ↗

August 22, 2025

Via Benzinga

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗

August 21, 2025

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.

Via Benzinga

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

August 21, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

An Overview of Ionis Pharmaceuticals's Earnings ↗

July 29, 2025

Via Benzinga

IONS Premarket Gains 2.4% After C-Suite Insider Sells $440K In Stock ↗

August 21, 2025

Ionis Pharmaceuticals rose 2.38% after hours following a planned stock sale by its chief scientific officer under a Rule 10b5-1 plan.

Via Benzinga

Ionis (IONS) Q2 Revenue Soars 101% ↗

July 31, 2025

Via The Motley Fool

Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) ↗

July 31, 2025

Via Benzinga

Ionis (IONS) Q2 2025 Earnings Call Transcript ↗

July 30, 2025

Via The Motley Fool

Topics Earnings

Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug ↗

July 30, 2025

Ionis reports surprise Q2 profit, raises 2025 forecast after strong Tryngolza launch and royalty gains push revenue past expectations.

Via Benzinga

Ionis reports second quarter 2025 financial results and highlights progress on key programs

July 30, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)

July 25, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice

July 21, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - A Strong Technical Setup Worth Watching ↗

July 18, 2025

IONIS Pharmaceuticals (NASDAQ:IONS) shows strong technicals with an 8/10 rating and a high-quality setup pattern, making it a breakout candidate for traders.

Via Chartmill

Ionis to hold second quarter 2025 financial results webcast

July 16, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

This Nike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

July 01, 2025

Via Benzinga

10 Analysts Assess Ionis Pharmaceuticals: What You Need To Know ↗

July 01, 2025

Via Benzinga

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

June 27, 2025

From Biogen Inc.

Via GlobeNewswire

Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma ↗

June 25, 2025

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing.

Via Benzinga

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

June 25, 2025

From Ionis Pharmaceuticals, Inc.

Via Business Wire

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

June 25, 2025

From Biogen Inc.

Via GlobeNewswire

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? ↗

June 25, 2025

Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version.

Via Investor's Business Daily

Analyst Expectations For Ionis Pharmaceuticals's Future ↗

June 12, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.